The results of reduced CD8+ naïve-T cell numbers and reduced activation capacity prior to CAR-T cell manufacturing in resistant patients led us to speculate that the reduced anti-tumour function of CAR-T cell products was already present in the initial-T cells, the source cells from which the CAR-T product was manufactured. Here, CD8A is linked to neoplasm.